Search results for: cancer

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

March 5, 2021 • By Michele B. Kaufman, PharmD, BCGP

In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.... [Read More]

Study Finds Increased Risk of Cancer in Psoriasis Patients

August 5, 2020 • By Lara C. Pullen, PhD

Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…... [Read More]

Malignant Complications: Screening for Cancer in Rheumatic Diseases

July 13, 2020 • By Jason Liebowitz, MD

Cancer and autoimmunity have a complex relationship. In a presentation, Ami Shah, MD, MHS, discussed how to use autoantibodies as tools for cancer risk stratification, how to approach cancer screening in individuals with new-onset disease and more…... [Read More]

Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19

May 29, 2020 • By Julie Steenhuysen

CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from… [Read More]

Cancer-Associated Myositis: A Case Report & Review of the Literature

February 17, 2019 • By Osman Bhatty, MD, Rouhin Sen, MD, & Joseph Nahas, MD

Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens… [Read More]

Scleroderma Autoantibodies Linked to Cancer Risk

November 18, 2018 • By Kurt Ullman

Recent studies point to a relationship between scleroderma and autoantibodies (e.g., anti-RNA polymerase III or anti-RNPC3), and an increased cancer risk within a short interval of scleroderma onset. Mechanistic studies provide further evidence that cancer may trigger scleroderma in patients with these autoantibodies. However, many questions remain unanswered. A study in the Annals of the… [Read More]

TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates

August 15, 2018 • By Will Boggs, MD

NEW YORK (Reuters Health)—Tumor necrosis factor (TNF) inhibitors do not appear to increase cancer-recurrence rates in patients with rheumatoid arthritis (RA), according to new findings from Sweden. TNF has both tumor-promoting and cancer-protective effects, so TNF inhibitors could conceivably affect the risk for cancer recurrence. However, few studies have reported the risk for cancer relapse… [Read More]

Dealing with Simultaneous Cancer & Rheumatic Disease

March 17, 2018 • By Thomas R. Collins

SAN DIEGO—New insights into how scleroderma and myositis may be linked with cancer have led to intriguing questions that could impact patient care, experts said at the 2017 ACR/ARHP Annual Meeting in November. Understanding the relationship between cancer and rheumatic diseases is important because rheumatologists are seeing more and more patients with both diseases, and… [Read More]

TNF Inhibitors May Not Be Linked to Cancer Risk in Kids

March 1, 2018 • By Rita Buckley

NEW YORK (Reuters Health)—Using tumor necrosis factor (TNF) inhibitors in children is not significantly associated with cancer risk, according to a new study. “TNF inhibitors are remarkably effective for the treatment of many autoimmune conditions, but physicians worry that they cause cancer,” Dr. Timothy Beukelman from the University of Alabama in Birmingham told Reuters Health… [Read More]